Aditya Bardia, MD, MPH

home / authors / aditya-bardia-md-mph-

Articles

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

Aditya Bardia, MD, MPH

March 14th 2022

Aditya Bardia, MD, MPH, discusses the use of endocrine therapy in estrogen receptor–positive breast cancer.

Practical Advice on the Use of ctDNA Testing in Breast Cancer

Aditya Bardia, MD, MPH;Barry P. Rosen, MD

February 16th 2022

Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.

Other Clinical Studies on ctDNA Use in Breast Cancer

Barry P. Rosen, MD ;Aditya Bardia, MD, MPH

February 16th 2022

Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

Sara A. Hurvitz, MD;Aditya Bardia, MD, MPH;Patrick Neven, MD, PhD;Kevin Kalinsky, MD, MS

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection

Aditya Bardia, MD, MPH;Barry P. Rosen, MD

February 9th 2022

A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.

Role of ctDNA in the Adjuvant Setting of Breast Cancer

Aditya Bardia, MD, MPH;Barry P. Rosen, MD

February 9th 2022

Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

Sara A. Hurvitz, MD;Aditya Bardia, MD, MPH;Patrick Neven, MD, PhD;Kevin Kalinsky, MD, MS

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

SABCS 2021 Updates in ER+ Breast Cancer

Sara A. Hurvitz, MD;Aditya Bardia, MD, MPH;Patrick Neven, MD, PhD;Kevin Kalinsky, MD, MS

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

<1 2 3 4